香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 星島新聞集團有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於二零二 六年三月二十五日（星期三）舉行董事會會議，藉以（其中包括）批准刊發本公司及 其附屬公司截至二零二五年十二月三十一日止年度末期業績公佈，考慮派發末期股 息的建議（如有），以及處理其他事項。 SING TAO NEWS CORPORATION LIMITED 星島新聞集團有限公司 * （於百慕達註冊成立之有限公司） （股份代號：1105） 董事會會議召開日期 承董事會命 星島新聞集團有限公司 公司秘書 岑家輝 香港，二零二六年三月十三日 於本公告日期，董事會成員包括：（ 1 ）執行董事：郭英成先生（聯席主席）、蔡加讚 先生（聯席主席）及郭曉亭女士（副主席兼行政總裁）；及（ 2 ）獨立非執行董事：胡 定旭先生、韓永紅女士及范駿華先生。 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 2. 股 ...

Group 1 - The core point of the article is the election of Jin Xi, a 26-year-old, as the chairman and general manager of Hongming Co., Ltd., making him one of the few "post-2000" chairmen in A-shares [2][6] - Jin Xi is the son of Jin Jian and Cai Tiehui, who are the controlling shareholders of Hongming Co., Ltd., holding over 60% of the company's shares [6] - Hongming Co., Ltd. specializes in providing high-quality packaging boxes, paper-plastic intelligent equipment, and complete automation solutions, with its products widely used in various packaging sectors [7] Group 2 - The company reported a net profit of -16.77 million yuan in 2023 and continued to incur losses in 2024, with a net profit of -9.77 million yuan [7][8] - Despite a 34.49% growth in overseas market business, the company faced slow recovery in downstream market demand and intense industry competition, leading to a decline in product sales prices [8] - For 2025, the company anticipates a net loss of between 12 million to 18 million yuan, attributed to low downstream investment demand and increased competition [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | -- ...

Core Viewpoint - Hongming Co., Ltd. is undergoing a board reshuffle as the current board's term is ending, with a focus on the transition to the next generation of leadership amid ongoing financial struggles [1][2]. Group 1: Board Reshuffle - The new board candidates include Jin Xi, Wang Peiyi, Liu Jiang, Zhong Shuidao, Zuo Yingkui, and Zhu Zhiwei, with Jin Xi and Wang Peiyi being notable as they represent the "second generation" of the founding family [2][3]. - Jin Xi, born in 2000, is the son of the company's founder and current chairman, Jin Jian, and has a strong educational background with degrees from New York University and Columbia University [2][3]. - Jin Jian and his wife, Cai Tiehui, who are the controlling shareholders holding over 60% of the company, will exit the board, marking a significant leadership change [3]. Group 2: Company Performance - Hongming Co., Ltd. has faced continuous financial difficulties since its listing on the Shenzhen Stock Exchange in December 2022, with negative net profits projected for 2023 and 2024 [2][5]. - In 2023, the company reported a net profit of -16.77 million yuan, and for 2024, the projected net profit is -9.77 million yuan, despite a 34.49% growth in overseas market business [5]. - The company has seen a decline in revenue, with a 13.93% decrease in the first three quarters of 2025, resulting in a net profit of -9.43 million yuan [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | | 本月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470 ...

Core Viewpoint - The collaboration between 加科思 and AstraZeneca involves a total transaction value of $20.15 billion, with 加科思's drug JAB-23E73 being the focal point, yet the stock price of 加科思 fell significantly on the first trading day after the announcement [1][2]. Group 1: Transaction Details - 加科思 will receive an upfront payment of $100 million, with potential milestone payments of up to $1.915 billion based on development and commercialization progress, along with royalties on net sales outside of China [1]. - JAB-23E73 targets various KRAS mutations, which are present in approximately 23% of all cancer patients, and is currently undergoing Phase I clinical trials in China and the U.S. [1]. Group 2: Partnership with AstraZeneca - AstraZeneca will have exclusive rights to develop and commercialize the drug outside of China, while 加科思 will co-develop and commercialize it within China [2]. - 加科思 chose AstraZeneca due to its significant revenue from oncology, which is projected to account for 41% of its income in 2024, and its established global clinical network [2]. Group 3: Market Reaction and Stock Performance - Following the announcement, 加科思's stock dropped by 17% at one point, closing down 13.58% at HKD 7.83, with a total market capitalization of HKD 6.16 billion [2]. - Analysts noted that the $100 million upfront payment may not meet market expectations, which were around $200 million [2]. Group 4: Management's Perspective - The CEO of 加科思 stated that the upfront payment represents 5% of the total transaction value, which is considered reasonable compared to industry standards [3]. - The CEO also addressed the stock price decline, attributing it to the early-stage development of the biotech sector in Hong Kong and the shift in investor focus from long-term value to short-term gains [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 2. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | | 本月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 47 ...

Core Viewpoint - A new individual business, Yuxi Hongta District Xingdao Dessert Shop, has been established with a registered capital of 150,000 RMB, focusing on food service and sales [1] Company Summary - The legal representative of the newly established dessert shop is He Jun Dong [1] - The business scope includes licensed projects such as catering services and food sales, which require approval from relevant authorities before operation [1] - The general projects include online sales of pre-packaged food and retail of fresh fruits, which can be conducted independently with a business license [1]